TP53 and large cell neuroendocrine carcinoma: Furthermore, we found that patients with comutation of TP53 and RB1 in cSCLC-LCNEC and SCLC had a worse DFS prognosis than LCNEC patients (3-year DFS rates: 75% in LCNEC, 16.7% in cSCLC-LCNEC, and 50% in SCLC; Fig. S6B).